MNMD(MNMD)
MNMD
Analyst Coverage
No analyst coverage available for this stock.
Key MetricsTTM
Market Cap$2.28B
Revenue TTM$0.00
Net Income TTM-$237.54M
Free Cash Flow-$174.34M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-102.5%
Return on Assets-59.2%
Debt / Equity0.00
Current Ratio4.69
EPS TTM$-2.18
PRICE
Prev Close
20.60
Open
20.15
Day Range19.95 – 21.10
19.95
21.10
52W Range4.70 – 21.08
4.70
21.08
98% of range
VOLUME & SIZE
Avg Volume
2.5M
FUNDAMENTALS
P/E Ratio
-10.4x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
45
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 96 days
Aug 25
MNMD News
About
Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Robert Barrow
Country
Canada
Website
Daniel Rollings KarlinChief Medical Officer
Gregg PrattChief Regulatory & Quality Assurance Officer
Scott FreemanCo-Founder & Clinical Advisor
Leonard LatchmanCo-founder
Mark R. SullivanChief Legal Officer & Corporate Secretary
Peter MackSenior Vice President of Pharmaceutical Development & Operations
Robert BarrowChief Executive Officer & Director
Beth CalitriVice President of Corporate Communications
Brandi L. RobertsChief Financial Officer
Stephanie FaganChief Corporate Affairs Officer